机器人辅助手术在老年可切除非小细胞肺癌中的比较效果
该匹配队列研究基于SEER-Medicare数据库纳入2766例65岁以上I-IIIA期NSCLC术后患者,比较机器人辅助手术(RAS)、开胸与电视辅助胸腔镜手术(VATS)的效果与费用。RAS并发症率低于开胸(OR 0.57),与VATS相似(OR 1.02);淋巴结分期与总生存无显著差异;
要点
- RAS并发症率低于开胸手术,但与VATS相似。
- RAS淋巴结分期充分性与开胸及VATS均无显著差异。
- RAS总生存与开胸及VATS无显著差异,费用高于VATS。
核心结论
- RAS较开胸手术改善手术结局,但可能并不优于VATS。
- 在广泛推广前需进一步评估RAS的比较效果。
研究设计与样本
- 基于SEER-Medicare数据库的匹配队列研究,纳入2766例65岁以上I-IIIA期NSCLC术后患者。
- 按年龄、性别、分期和切除范围匹配,采用倾向评分法比较调整后的并发症率、淋巴结分期、生存和治疗相关费用。
主要发现
- RAS并发症率低于开胸(OR 0.57;95%CI 0.42-0.79),与VATS相似(OR 1.02;95%CI 0.76-1.37)。
- RAS淋巴结采样充分性与开胸(OR 1.28;95%CI 0.94-1.74)或VATS(OR 0.88;95%CI 0.66-1.18)无显著差异。
- RAS与开胸(HR 0.81;95%CI 0.63-1.04)或VATS(HR 0.91;95%CI 0.70-1.18)的总生存无显著差异。
临床怎么用
- 老年可切除NSCLC选择RAS需权衡其较开胸更低的并发症率与较VATS更高的费用。
- RAS在淋巴结分期和生存方面未显示优于VATS,广泛采用前应进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Robotic-assisted surgery (RAS) is a novel surgical approach increasingly used for patients with non-small cell lung cancer (NSCLC). However, data comparing the effectiveness and costs of RAS vs open thoracotomy and video-assisted thoracoscopic surgery (VATS) for NSCLC are limited. METHODS: Patients > 65 years old with stage I to IIIA NSCLC treated with RAS, VATS, or open thoracotomy were identified from the Surveillance, Epidemiology, and End Results-Medicare database and matched according to age, sex, stage, and extent of resection. Propensity score methods were used to compare adjusted rates of postoperative complications, adequate lymph node staging, survival, and treatment-related costs. RESULTS: In this matched study cohort of 2,766 patients with resected NSCLC, RAS was associated with lower complication rates (OR, 0.57; 95% CI, 0.42-0.79) compared with open thoracotomy, and similar complication rates (OR, 1.02; 95% CI, 0.76-1.37) compared with VATS. Patients undergoing RAS were as likely to have adequate lymph node sampling as those undergoing open thoracotomy (OR, 1.28; 95% CI, 0.94-1.74) or VATS (OR, 0.88; 95% CI, 0.66-1.18). There was no significant difference in overall survival after RAS vs open thoracotomy (hazard ratio, 0.81; 95% CI, 0.63-1.04) or VATS (hazard ratio, 0.91; 95% CI, 0.70-1.18). Costs were similar for RAS ($54,702) vs open thoracotomy ($57,104; P = .08), and higher compared with VATS ($48,729; P = .02). CONCLUSIONS: RAS led to improved operative outcomes compared with open thoracotomy but may not offer an advantage over VATS. The comparative effectiveness of RAS should be further evaluated prior to widespread adoption.
引用
- Veluswamy RR, Whittaker Brown SA, Mhango G, et al. Comparative Effectiveness of Robotic-Assisted Surgery for Resectable Lung Cancer in Older Patients. Chest. 2019. PMID: 31589843. doi:10.1016/j.chest.2019.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。